• 제목/요약/키워드: 9-hydroxypheophorbide-a(9-HpbD-a)

검색결과 3건 처리시간 0.013초

Mechanism of Photodynamic Therapy using 9-hydroxypheophorbide-alpha on HeLa Cell Lines

  • 안진철
    • 대한의생명과학회지
    • /
    • 제15권2호
    • /
    • pp.153-160
    • /
    • 2009
  • Photodynamic therapy(PDT) is a treatment utilizing the generation of singlet oxygen and other reactive oxygen species(ROS), which selectively accumulate in target cells. The aim of present work is to investigate the photodynamic therapy mechanism of 9-HpbD-a-mediated PDT in HeLa cell lines. We studied the general reactive oxygen species(G-ROS) activation after 9-HpbD-a PDT using fluorescence stain with $H_2DCF-DA$. G-ROS activation observed after 9-HpbD-a PDT and higher activation condition was 1 hour after PDT at 0.5 ${\mu}g/ml$ 9-HpbD-a concentration. Sodium azide and reduced glutathione(the singlet oxygen quencher) could protect HeLa cells from cell death induced by 9-HpbD-a PDT. But D-mannitol(the hydroxyl radical scavenger) could not protect cell death. Singlet oxygen played a decisive role in 9-HpbD-a PDT induced HeLa cell death. Type II reaction was the main type of ROS formation at 9-HpbD-a PDT.

  • PDF

9-hydroxypheophorbide-a와 660 nm 다이오드 레이저를 이용한 광역학치료의 항암효과와 치료기전에 대한 연구 (The Anticancer Effect and Mechanism of Photodynamic Therapy Using 9-Hydroxypheophorbide-a and 660 nm Diode Laser on Human Squamous Carcinoma Cell Line.)

  • 안진철
    • 생명과학회지
    • /
    • 제19권6호
    • /
    • pp.770-780
    • /
    • 2009
  • 녹조류인 Spirulina platensis에서 추출하여 만든 새로운 광감작제와 660 nm의 다이오드 레이저를 이용한 광역학치료의 항암효과와 치료기전을 알아보았다. 세포 독성능은 MTT assay를 이용하였고, 세포사멸기전은 propidium iodide과 Hoechst 33342 염색법과 투과전자현미경으로 확인하였다. 또한 암세포가 이종 이식된 누드마우스 모델에서 광역학치료를 시행하여 항암효과를 확인하였다. 3종류의 클로로필 유도체 중 9-hydroxypheophorbide-a (9-HpbD-a)의 세포 독성능이 가장 우수하였고, 9-HpbD-a의 적정 레이저조사 시간은 30분 (3.2 J/$cm^{2}$), 광감작제를 투여하고 레이저조사시간까지의 배양시간은 최소 6시간 이상임을 확인하였다. 광역학치료의 세포사멸기전은 낮은 9-HpbD-a 농도에서 세포고사가 주된 세포사멸기전이었고, 높은 농도의 9-HpbD-a에서는 세포괴사에 의한 세포사멸이 주된 기전임을 확인하였다. 투과전자현미경 하에서도 같은 양상을 관찰하였다. 그리고 암세포가 이종 이식된 누드마우스 모델에서의 광역학치료는 제1군 정상대조군과 제2군 9-HpbD-a만을 투여한 종양조직모두 지속적인 종양의 성장(100% )을 보였고, 제3군인 레이저만을 종양조직에 조사한 실험군에서는 3 마리는 치료가 되지 않았고(75.0%), 1 마리는 재발(25.0%) 하였다. 제4군 광역학치료군에서 총16 마리의 종양에서 10 마리는 완치(62.5%), 4 마리는 재발(25.0%), 2 마리는 치유되지 않았음(12.5% )을 확인하였다. 9-HpbD-a와 660 nm 다이오드 레이저를 이용한 광역학치료는 유의한 항암효과를 나타내었고 9-HpbD-a를 이용한 광역학치료는 새로운 치료방법으로서 향후 암치료의 유용한 치료방법으로 기대된다.

인체 편평상피세포암세포주에서 9-Hydroxypheophorbide-$\alpha$와 660nm Diode 레이저를 이용한 광역학치료의 항암효과 (Anticancer Effect of Photodynamic Therapy using 9-Hydroxypheophorbide-$\alpha$ and 660nm Diode Laser on Human Squamous Cell Carcinoma Cell Line)

  • 김한균
    • 대한두경부종양학회지
    • /
    • 제17권1호
    • /
    • pp.3-7
    • /
    • 2001
  • Objectives: New photosensitizer 9-hydroxypheophorbide-$\alpha$(9-HpbD-$\alpha$) was derived from chlorophyll in water with peak absorption at 660nm. 9-HpbD-$\alpha$ was tested with 660 nm diode laser for the anticancer effect of photodynamic therapy. Materials and Methods: Human SNU 1041 cells were seeded into 96 well plate at a density of $$ cells/well for 24 hours. Cells were washed with media containing various concentration of 9-HpbD-$\alpha$ ranging from $0{\mu}g/ml\;to\;3.75{\mu}g/ml$. Then, laser treatment was done with 660nm diode laser ($10mW/cm^2$) at various time setting (0, 30, 60, 90, 120 minutes) and with various time interval (0, 1, 4, 6, 18 hours). The treated cells were incubated 48 hours and MTT assay was done to measure the viability of cells. Results: The viability of cells was more than 90% after laser treatment in control group. The viability of cells was decreased with increasing concentration of 9-HpbD-$\alpha$ and laser treatment time in experimental groups. The viability of cells was decreased significantly as the interval time between addition of 9-HpbD-$\alpha$ and laser irradiation was increased. Conclusion: This study shows the anticancer effect of photodynamic therapy using 9-HpbD-$\alpha$ and 660nm Diode laser on carcinoma cell line. 9-HpbD-$\alpha$ is considerd as one of new photo sensitizers in the field of photodynamic therapy.

  • PDF